Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
BMEA
BMEA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BMEA News
Biomea Fusion to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Dec 17 2025
Globenewswire
Biomea Fusion Unveils Clinical Results of Icovamenib, Advancing Diabetes Treatment
Dec 10 2025
Globenewswire
Biomea Fusion Unveils Clinical Results of Icovamenib, Advancing Diabetes Treatment
Dec 10 2025
Newsfilter
Biomea Fusion Highlights Long-lasting Advantages of Menin Inhibitor for Type 2 Diabetes
Dec 05 2025
NASDAQ.COM
Biomea Fusion Presents COVALENT-111 Study Results, New Breakthrough in Diabetes Treatment
Dec 05 2025
Globenewswire
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain
Dec 03 2025
NASDAQ.COM
Biomea Fusion Grants 7,500 Stock Options to New Employee
Dec 01 2025
Newsfilter
Citigroup Reaffirms Buy Rating on Biomea Fusion, Adjusts Price Target to $6
Nov 10 2025
Benzinga
D. Boral Capital Reaffirms Buy Rating on Biomea Fusion, Adjusts Price Target to $12
Nov 05 2025
Benzinga
Biomea Fusion to Join Citi's SMID Biotech C-Suite Fireside Chat Series
Oct 21 2025
Newsfilter
Biomea Fusion to Join Citi's SMID Biotech Executive Fireside Chat Series
Oct 21 2025
Yahoo Finance
Biomea Fusion Announces Phase 2 Diabetes Data and Initiates Stock Offering
Oct 06 2025
Yahoo Finance
Biomea Fusion Unveils Plans for Public Securities Offering
Oct 06 2025
Newsfilter
Most Active Stocks After Hours on October 6, 2025: SOFI, BMEA, PPH, NVDA, CSCO, CMCSA
Oct 06 2025
NASDAQ.COM
Biomea Fusion Gains Ground Following Type 2 Diabetes Drug Results
Oct 06 2025
SeekingAlpha
D. Boral Capital Continues to Recommend Buying Biomea Fusion (BMEA)
Oct 04 2025
NASDAQ.COM
Show More News
